H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 15.1% of adults in New Orleans have diagnosed diabetes — 3.1 points above the U.S. 12% figure. Census population 383,997. Louisiana Medicare wound biologics: Novitas Solutions (JH). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed New Orleans clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a New Orleans storefront.
Skin Substitute Therapy Products in New Orleans, LA for clinics & physicians. Skin substitute therapy for… Compliance support & pricing — contact Hawk Medical.
Adult obesity in New Orleans is 34% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 15.1% of adults in New Orleans have diagnosed diabetes — 3.1 points above the U.S. 12% figure. Louisiana includes CDC Diabetes Belt counties, so DFU planning belongs in the annual budget. Hawk Medical is the distributor for skin substitute therapy, not a walk-in clinic.
National Skin Substitute Therapy Products notes (how the product actually works)America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For New Orleans we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 15.1% of adults in New Orleans have diagnosed diabetes — 3.1 points above the U.S. 12% figure.
If you already buy skin substitute therapy elsewhere, use this page as a check: homologous-use language, current Novitas Solutions article IDs, and PLACES 15.1% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 15.1% of adults — 3.1 points above the U.S. 12% figure. Obesity is 34%; arthritis is 25.3%. That is place-level BRFSS modeling, not a clinic census and not a New Orleans trial.
The allograft is used to perform the same basic function in the recipient as in the donor (FDA 361). Using umbilical or amniotic tissue as a marketed “stem cell cure” for unrelated conditions is outside that lane and is a Louisiana compliance risk.
No. PRP (autologous) and cellular/tissue products (allograft/skin substitutes) sit on different coding and coverage paths. Novitas Solutions LCDs for CTPs do not automatically cover PRP injections. Build separate protocols and fee tickets.
Louisiana is in CMS MAC JH, administered by Novitas Solutions. CTP and skin-substitute coverage is written at the MAC level. Confirm the current LCD/article before you set utilization — we help practices map product to those rules; we do not override them.
If you operate in Louisiana and another MAC state, say it on the first call. JH will not port 1:1. We would rather split utilization than watch a sister clinic copy New Orleans tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in New Orleans, LA.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for New Orleans is JH geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for New Orleans — 3.1 points above the U.S. 12% figure. Planning input, not an outcomes claim.
Louisiana Part B wound biologics follow this contractor (siblings: AR, CO, MS, NM, OK, TX). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in New Orleans. Useful for joint-program math; still needs a diagnosis and privileging.
No New Orleans storefront. Joe Bradley is an active practice owner. skin substitute therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.